← Leaderboards
Marie-Claire Elisabeth Gauduin
Harvard Medical School
$15,247,447
Attributed
$20,818,457
Total exposure
26
Grants
25
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.8M · FY2008–25$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,818,457 · 26
By mechanism
R01$17,559,531 · 5
P51$1,902,422 · 19
R56$847,754 · 1
R21$508,750 · 1
Top collaborators
- Francois J Villinger7 shared
- Chinnaswamy Jagannath5 shared
Others in their field
Top investigators on “Immune Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$680,290,567
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,695,345
- Barton F Haynes · Duke University$456,664,915
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$309,708,725
- Peter B. Gilbert · Fred Hutchinson Cancer Center$192,329,665
Research focus
Immune ResponseInfectionVaccinesViralSourceVirusResponseAcquired Immunodeficiency SyndromeImmune SystemCellsTransmission ProcessVaginaMacacaAntigensAnimalsVaccinatedT-LymphocyteUnited States National Institutes Of HealthImmunizationDoseImmunityMucosal SiteSiteHiv Vaccine
Grant awards (42)
Durable HIV Vaccine Targeting Mucosal Epithelium$963,873
R01 · FY2025 · AI · contact PI
Intrarectal Immunization for a Barrier to Mucosal HIV Infection$903,547
R01 · FY2025 · AI · contact PI
Intrarectal Immunization for a Barrier to Mucosal HIV Infection$984,626
R01 · FY2024 · AI · contact PI
Durable HIV Vaccine Targeting Mucosal Epithelium$970,600
R01 · FY2024 · AI · contact PI
Durable HIV Vaccine Targeting Mucosal Epithelium$887,962
R01 · FY2024 · AI · contact PI
Durable HIV Vaccine Targeting Mucosal Epithelium$939,000
R01 · FY2023 · AI · contact PI
Durable HIV Vaccine Targeting Mucosal Epithelium$989,873
R01 · FY2022 · AI · contact PI
A Neonatal Monkey Model of Tuberculosis Vaccination$893,080
R01 · FY2021 · AI
A Neonatal Monkey Model of Tuberculosis Vaccination$896,046
R01 · FY2020 · AI
A Neonatal Monkey Model of Tuberculosis Vaccination$919,284
R01 · FY2019 · AI
A Neonatal Monkey Model for Tuberculosis Vaccination$890,384
R01 · FY2018 · AI
Trans-complementing papillioma virus for AIDS vaccine$859,068
R01 · FY2018 · AI · contact PI
A Neonatal Monkey Model for Tuberculosis Vaccination$903,746
R01 · FY2017 · AI
Trans-complementing papillioma virus for AIDS vaccine$857,135
R01 · FY2017 · AI · contact PI
Trans-complementing papillioma virus for AIDS vaccine$776,478
R01 · FY2016 · AI · contact PI
Recombinant Papillomavirus-based HIV Vaccine Targeting Genital Mucosa$231,250
R21 · FY2016 · AI · contact PI
Trans-complementing papillioma virus for AIDS vaccine$904,454
R01 · FY2015 · AI · contact PI
Recombinant Papillomavirus-based HIV Vaccine Targeting Genital Mucosa$277,500
R21 · FY2015 · AI · contact PI
Antigen presentation by epithelial stem cells to promote life long immunity$712,909
R01 · FY2013 · AI · contact PI
Antigen presentation by epithelial stem cells to promote life long immunity$744,517
R01 · FY2012 · AI · contact PI
Antigen presentation by epithelial stem cells to promote life long immunity$781,940
R01 · FY2011 · AI · contact PI
EPITHELIAL CELLS AS MUCOSAL ADJUVANT FOR LIFE LONG IMMUNITY$340,953
P51 · FY2011 · RR · contact PI
EFFICACY OF A DNA/MVA VACCINE TO PROTECT AGAINST REPEATED VAGINAL SIV CHALLENGE$195,436
P51 · FY2011 · RR · contact PI
TB INFECTION IN NHP MODEL OF PEDIATRIC AIDS$181,646
P51 · FY2011 · RR · contact PI
T-CELL FUNCTION IN PEDIATRIC AIDS$69,650
P51 · FY2011 · RR · contact PI
EARLY MECHANISMS OF HIV TRANSMISSION USING THE SIV/MACAQUE MODEL FOR AIDS$13,990
P51 · FY2011 · RR · contact PI
Antigen presentation by epithelial stem cells to promote life long immunity$781,009
R01 · FY2010 · AI · contact PI
EPITHELIAL CELLS AS MUCOSAL ADJUVANT FOR LIFE LONG IMMUNITY$342,182
P51 · FY2010 · RR · contact PI
EFFICACY OF A DNA/MVA VACCINE TO PROTECT AGAINST REPEATED VAGINAL SIV CHALLENGE$202,435
P51 · FY2010 · RR · contact PI
HUMORAL AND CELLULAR IMMUNE RESPONSES AGAINST SHIV INFECTION$63,426
P51 · FY2010 · RR · contact PI
MODIFIED HIV ENV IMMUNOGENS$29,315
P51 · FY2010 · RR · contact PI
EARLY MECHANISMS OF HIV TRANSMISSION USING THE SIV/MACAQUE MODEL FOR AIDS$19,188
P51 · FY2010 · RR · contact PI
T-CELL FUNCTION IN PEDIATRIC AIDS$13,858
P51 · FY2010 · RR · contact PI
Epithelial Cells as Mucosal Adjuvant for Life Long Immunity$847,754
R56 · FY2009 · AI · contact PI
EFFICACY OF A DNA/MVA VACCINE TO PROTECT AGAINST REPEATED VAGINAL SIV CHALLENGE$199,721
P51 · FY2009 · RR · contact PI
HUMORAL AND CELLULAR IMMUNE RESPONSES AGAINST SHIV INFECTION$43,831
P51 · FY2009 · RR · contact PI
T-CELL FUNCTION IN PEDIATRIC AIDS$17,148
P51 · FY2009 · RR · contact PI
EARLY MECHANISMS OF HIV TRANSMISSION USING THE SIV/MACAQUE MODEL FOR AIDS$9,995
P51 · FY2009 · RR · contact PI
EFFICACY OF A DNA/MVA VACCINE TO PROTECT AGAINST REPEATED VAGINAL SIV CHALLENGE$129,768
P51 · FY2008 · RR · contact PI
T-CELL FUNCTION IN PEDIATRIC AIDS$14,908
P51 · FY2008 · RR · contact PI
MODIFIED HIV ENV IMMUNOGENS$7,486
P51 · FY2008 · RR · contact PI
HUMORAL AND CELLULAR IMMUNE RESPONSES AGAINST SHIV INFECTION$7,486
P51 · FY2008 · RR · contact PI